{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-168501","form_type":"8-K","ticker":"SVRA","cik":"0001160308","company_name":"Savara Inc","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.489520+00:00","generated_at":"2026-06-01T01:20:06.228679+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met","bullets":["Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).","Statistically significant improvement sustained at Week 48: DLCO 6.90% (p=0.0008).","SGRQ Total Score statistically significant at Week 24 (-6.59 points, p=0.0072); SGRQ Activity and exercise capacity nominally significant.","Well-tolerated; no drug-related discontinuations; 97% completed double-blind; all patients elected 96-week open-label.","Company plans to complete BLA submission to FDA in first half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-168501","json":"https://secwatch.observer/filing/0001193125-24-168501.json","markdown":"https://secwatch.observer/filing/0001193125-24-168501.md","text":"https://secwatch.observer/filing/0001193125-24-168501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1160308/000119312524168501/0001193125-24-168501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1160308/000119312524168501/d860197d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:20:06.228679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}